welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Sarepta Announces Clinical Hold Lifted for its Duchenne Muscular Dystrophy Micro-dystrophin Gene Therapy Program
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, announced today that the Food and Drug Administration (FDA) has lifted the clinical hold for the Company’s Duchenne muscular dystrophy (DMD) micro-dystrophin gene therapy program. Sarepta previously announced on July 25, 2018, that the FDA placed the program on clinical hold due to the presence of trace amounts of DNA fragment in research-grade third-party supplied plasmid in a manufacturing lot. In response, and in collaboration with Nationwide Children’s Hospital, an action plan was developed and submitted to the FDA, including an audit of the plasmid supplier and a commitment to use GMP-s plasmid for all future production lots.
rareRelated
-
Evaluation of Muscle miRNA as Biomarkers in DystrophinopathiesDuchenne muscular dystrophy (DMD), cause...
-
Sarepta Therapeutics and Jerry R. Mendell, M.D. to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Progra...Sarepta Therapeutics, Inc., a commercial...
-
Capricor places Duchenne drug trial on holdCapricor Therapeutics Inc said on Wednes...
-
Gene Editing CRISPR/Cas9 Therapy for Duchenne Muscular Dystrophyhttps://www.youtube.com/watch?v=8xNh1qr4...
-
Study of ataluren in previously treated participants with nonsense mutation dystrophinopathy (nmDBMD)The objective of this study is to assess...
-
Inside “Custom Cars” For Gene DeliveryGene therapy shows great promise to be p...
-
Ataluren: An Overview of Clinical Trial Results in Nonsense Mutation Duchenne Muscular DystrophyObjective: Provide an overview of atalu...